Key Points
- Insider Scott Bizily sold 1,635 shares of 4D Molecular Therapeutics on Nov. 17 at an average price of $10.59, reducing his position by 31.27% to 3,594 shares, as disclosed in an SEC filing.
- Bizily has been a frequent seller in recent months, including transactions on Oct. 24 (2,678 shares), Oct. 16 (1,635), Oct. 9 (2,408) and Sept. 23 (2,407), indicating consecutive insider selling.
- 4D Molecular's stock traded around $10.96 (up ~1.4%), with a market cap near $626M; the company reported negative EPS and weak revenue last quarter, while analysts hold a consensus "Moderate Buy" with an average target of $28.70.
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Get Free Report) insider Scott Bizily sold 1,635 shares of the stock in a transaction that occurred on Monday, November 17th. The shares were sold at an average price of $10.59, for a total value of $17,314.65. Following the transaction, the insider owned 3,594 shares in the company, valued at approximately $38,060.46. This trade represents a 31.27% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.
Scott Bizily also recently made the following trade(s):
- On Friday, October 24th, Scott Bizily sold 2,678 shares of 4D Molecular Therapeutics stock. The stock was sold at an average price of $12.00, for a total transaction of $32,136.00.
- On Thursday, October 16th, Scott Bizily sold 1,635 shares of 4D Molecular Therapeutics stock. The stock was sold at an average price of $10.17, for a total transaction of $16,627.95.
- On Thursday, October 9th, Scott Bizily sold 2,408 shares of 4D Molecular Therapeutics stock. The stock was sold at an average price of $10.00, for a total transaction of $24,080.00.
- On Tuesday, September 23rd, Scott Bizily sold 2,407 shares of 4D Molecular Therapeutics stock. The shares were sold at an average price of $8.00, for a total transaction of $19,256.00.
4D Molecular Therapeutics Trading Up 1.4%
NASDAQ:FDMT traded up $0.16 during mid-day trading on Thursday, hitting $10.96. The company's stock had a trading volume of 238,231 shares, compared to its average volume of 856,708. The company has a market capitalization of $625.86 million, a price-to-earnings ratio of -2.92 and a beta of 2.96. 4D Molecular Therapeutics, Inc. has a fifty-two week low of $2.23 and a fifty-two week high of $12.34. The stock has a fifty day moving average of $9.54 and a 200-day moving average of $6.43.
4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) last released its quarterly earnings data on Monday, November 10th. The company reported ($1.01) earnings per share for the quarter, beating the consensus estimate of ($1.02) by $0.01. 4D Molecular Therapeutics had a negative return on equity of 47.27% and a negative net margin of 174,314.17%.The company had revenue of $0.09 million for the quarter, compared to analyst estimates of $0.40 million. On average, equities analysts anticipate that 4D Molecular Therapeutics, Inc. will post -2.84 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
Several research analysts have issued reports on the company. Barclays dropped their price objective on 4D Molecular Therapeutics from $38.00 to $33.00 and set an "overweight" rating for the company in a research note on Tuesday, November 11th. Wall Street Zen upgraded shares of 4D Molecular Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, November 15th. Chardan Capital lifted their price target on shares of 4D Molecular Therapeutics from $25.00 to $26.00 and gave the company a "buy" rating in a report on Tuesday, November 11th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of 4D Molecular Therapeutics in a research note on Wednesday, October 8th. Finally, Morgan Stanley upgraded shares of 4D Molecular Therapeutics from an "underweight" rating to an "equal weight" rating in a research note on Friday, November 7th. Eight research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, 4D Molecular Therapeutics has a consensus rating of "Moderate Buy" and an average target price of $28.70.
View Our Latest Research Report on 4D Molecular Therapeutics
Hedge Funds Weigh In On 4D Molecular Therapeutics
Institutional investors have recently modified their holdings of the stock. Dimensional Fund Advisors LP grew its stake in shares of 4D Molecular Therapeutics by 3.7% during the third quarter. Dimensional Fund Advisors LP now owns 58,006 shares of the company's stock valued at $504,000 after purchasing an additional 2,069 shares during the last quarter. Russell Investments Group Ltd. increased its stake in shares of 4D Molecular Therapeutics by 11.7% in the 2nd quarter. Russell Investments Group Ltd. now owns 21,816 shares of the company's stock valued at $81,000 after buying an additional 2,284 shares during the period. Prelude Capital Management LLC raised its position in shares of 4D Molecular Therapeutics by 11.1% during the third quarter. Prelude Capital Management LLC now owns 23,000 shares of the company's stock worth $200,000 after acquiring an additional 2,300 shares during the last quarter. Farther Finance Advisors LLC raised its position in shares of 4D Molecular Therapeutics by 117.4% during the third quarter. Farther Finance Advisors LLC now owns 4,952 shares of the company's stock worth $43,000 after acquiring an additional 2,674 shares during the last quarter. Finally, Peapod Lane Capital LLC boosted its holdings in 4D Molecular Therapeutics by 1.1% in the third quarter. Peapod Lane Capital LLC now owns 322,081 shares of the company's stock valued at $2,799,000 after acquiring an additional 3,544 shares during the last quarter. 99.27% of the stock is owned by institutional investors.
About 4D Molecular Therapeutics
(
Get Free Report)
4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
